

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising a blend of granule and extragranule material, wherein said a granule is comprised of ibuprofen and a narcotic analgesic in a single phase, and wherein said extragranule material is comprised of at least one excipient.

Claim 2 (Cancelled).

3. (Previously Presented) A tablet composition comprising the compressed composition of claim 1.

4. (Currently Amended) A pharmaceutical tablet composition comprising:

- a) an effective amount of ibuprofen;
- b) an effective amount of a narcotic analgesic;
- c) colloidal silicon dioxide wherein the weight of the colloidal silicon dioxide is provided in a range, of the total weight of the table, of about 0.5% to about 3%;
- d) a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose;
- e) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and a sodium starch glycolate;
- f) a binder consisting of an akyhydroxy methylcellulose wherein the weight of the binder is provided in a range, of the total weight of the table composition, of about 2% to less than 6%;
- g) a starch provided in a weight range, of total weight of the tablet composition, of about 11% to about 28%; and
- h) a lubricant wherein the lubricant is provided in an amount less than 1% by weight of the total weight of the tablet; wherein the tablet comprises a compressed blend of a granule and extra granule material wherein the granule comprises at least apportion of the ibuprofen, at least a portion of the narcotic analgesic, a portion of the colloidal silicon dioxide, a portion of the disintegrant, and a portion of the starch and the weight of

the extra granule material is provided in a range of up to about 25% of the weight of the whole tablet, wherein said tablet is substantially free of lactose.

5. (Original) The composition as recited in claim 4 wherein the weight of the filler is provided in a range, of the total weight of the table composition, of about 10% to about 42%.

6. (Original) The composition as recited in claim 4 wherein the weight of the disintegrant is provided in a range, of the total weight of the tablet composition, of about 4% to about 10%.

7. (Original) The composition as recited in claim 5 wherein the weight of the disintegrant is provided in a range, of the total weight of the tablet composition, of about 4% to about 10%.

8. (Currently Amended) A pharmaceutical tablet composition comprising:

- (a) an effective amount of ibuprofen wherein the weight of the ibuprofen is provided in a range, of the total weight of the tablet composition, of up to about 50%;
- (b) an effective amount of hydrocodone;
- (c) colloidal silicon dioxide provided in a range, by total weight of the tablet composition, of about 1.5% to about 2%;
- (d) microcrystalline cellulose provided in a range, of the total weight of the tablet composition, of about 15% to about 25%;
- (e) a disintegrant selected from the group consisting of croscarmellose sodium and crospovidone wherein the weight of the disintegrant is provided in a range, of the total weight of the tablet composition, of about 6 to about 8%;
- (f) a binder consisting of an alkylhydroxy methylcellulose wherein the weight of the binder is provided in a range, of the total weight of the tablet composition, of about 3 % to about 4 %;
- (g) corn starch wherein the weight of the corn starch is provided in a range, of the total weight of the tablet composition, of about 11 to about 17 %; and
- (h) a lubricant wherein the weight of the lubricant is provided in an amount less than 1% by weight of the total weight of the tablet, wherein said tablet is substantially free of lactose.